Ensysce Biosciences, Inc.

For the period ended Jun 30, 2026. Filed Aug 13, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 13, 2026

ENSC$0.36-0.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 1. Consolidated Statements of Operations

Consolidated Statements of Operations

	Three Months Ended June 30,		Six Months Ended June 30,
	2026	2025	2026	2025
Federal grants	$1,164,315	$1,371,438	$2,125,313	$2,691,210
Operating expenses:
Research and development	2,471,752	1,923,430	5,818,633	3,808,957
General and administrative	1,268,952	1,198,523	2,445,299	2,600,279
Total operating expenses	3,740,704	3,121,953	8,263,932	6,409,236
Loss from operations	(2,576,389)	(1,750,515)	(6,138,619)	(3,718,026)
Other income (expense):
Change in fair value of liability classified warrants	-	(853)	-	9,063
Interest expense, net	(320)	(3,160)	(4,243)	(7,017)
Other income and expense, net	5,834	21,011	15,572	36,890
Total other income (expense), net	5,514	16,998	11,329	38,936
Net loss	$(2,570,875)	$(1,733,517)	$(6,127,290)	$(3,679,090)
Net loss attributable to noncontrolling interests	(166)	(166)	(166)	(166)
Deemed dividend related to warrants down round provision	-	-	-	-
Net loss attributable to common stockholders	$(2,570,709)	$(1,733,351)	$(6,127,124)	$(3,678,924)
Net loss per basic and diluted share:
Net loss per share attributable to common stockholders, basic and diluted	$(0.20)	$(0.79)	$(0.62)	$(2.04)
Weighted average common shares outstanding, basic and diluted	13,035,632	2,202,299	9,954,626	1,803,393

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.